Brammer Bio investing $50M in gene-therapy facility

Gene therapy

A brand-new CDMO is pushing forward with plans to be a player in gene-based drug manufacturing with a new manufacturing facility in a U.S. biotech hub.

Lexington, MA-based Brammer Bio laid out its plans at the BIO International event in San Francisco, saying it will spend about $50 million to outfit and staff a 50,000-square-foot facility in its home city for production of late-stage and commercial-scale viral vector and cell-based therapies.

Brammer Bio expects the facility to be operating by Q2 of next year. The plan is to eventually add 200 employees to its workforce there.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Brammer Bio was formed in March through the merger of Brammer Biopharmaceuticals and Alachua, FL-based Florida Biologix, with the help of a capital infusion from Ampersand Capital Partners, Florida Biologix's majority owner.

"The Lexington facility will be equipped for largescale manufacturing with a focus on compliance in these emerging drug categories,” Richard Snyder, Brammer CSO, said in a statement.

The company also has 45,000 square feet of process development and Phase I/II clinical manufacturing space in Alachua, FL, and intends to double that.

As more and more of the specialty drugs being developed by biotech and pharma are gene-based therapies, Brammer joins Japan’s Fujifilm Diosynth Biotechnologies and others like Swiss CDMO Lonza, in hustling to build or expand facilities to manufacture them.

- read the announcement 

Related Articles: 
New player jumping into cell therapies manufacturing 
Merck to outfit $60M biologics plant for Fujifilm to use

Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.